This paper summarizes the data from updated international protocols and guidelines for
diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). The invasive and non …

Considering the rare incidence of transthyretin amyloidosis cardiomyopathy (ATTR-CM) in
Poland, patients encounter difficulties at the stages of diagnosis and treatment. For …

Cardiomyopathy is a manifestation of transthyretin amyloidosis (ATTR), which is an
underrecognized systemic disease whereby the transthyretin protein misfolds to form fibrils …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed disease
associated with high mortality rates and the patient journey is characterized by increased …

Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a life‐threatening condition with a
heterogeneous clinical presentation. The recent availability of treatment for ATTR‐CM has …

Amyloidosis is caused by extracellular deposition of insoluble abnormal fibrils constituted by
misfolded proteins, which can modify tissue anatomy and hinder the function of multiple …

Transthyretin‐related amyloidosis (ATTR) is a subgroup of amyloidosis that results from
extracellular misassembled and toxic amyloid deposits affecting multiple organ systems, and …

Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal and
under-recognized disease. This targeted literature review assessed the extent and …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive,
infiltrative disease caused by the deposition of transthyretin amyloid fibrils in the heart, and …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly important but under-
recognized cause of heart failure in persons over 60 years of age. Transthyretin amyloid …